Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2006 1
2007 1
2012 1
2013 1
2014 2
2015 2
2016 1
2018 1
2019 3
2020 1
2021 5
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Prevention of osteoporosis in cystic fibrosis.
Chedevergne F, Sermet-Gaudelus I. Chedevergne F, et al. Curr Opin Pulm Med. 2019 Nov;25(6):660-665. doi: 10.1097/MCP.0000000000000624. Curr Opin Pulm Med. 2019. PMID: 31567515 Review.
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
Dreano E, Burgel PR, Hatton A, Bouazza N, Chevalier B, Macey J, Leroy S, Durieu I, Weiss L, Grenet D, Stremler N, Ohlmann C, Reix P, Porzio M, Roux Claude P, Rémus N, Douvry B, Montcouquiol S, Cosson L, Mankikian J, Languepin J, Houdouin V, Le Clainche L, Guillaumot A, Pouradier D, Tissot A, Priou P, Mély L, Chedevergne F, Lebourgeois M, Lebihan J, Martin C, Zavala F, Da Silva J, Lemonnier L, Kelly-Aubert M, Golec A, Foucaud P, Marguet C, Edelman A, Hinzpeter A, de Carli P, Girodon E, Sermet-Gaudelus I, Pranke I; French CF Reference Network study group. Dreano E, et al. Among authors: chedevergne f. Eur Respir J. 2023 Oct 19;62(4):2300110. doi: 10.1183/13993003.00110-2023. Print 2023 Oct. Eur Respir J. 2023. PMID: 37696564
Predictive factors for lumacaftor/ivacaftor clinical response.
Masson A, Schneider-Futschik EK, Baatallah N, Nguyen-Khoa T, Girodon E, Hatton A, Flament T, Le Bourgeois M, Chedevergne F, Bailly C, Kyrilli S, Achimastos D, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Masson A, et al. Among authors: chedevergne f. J Cyst Fibros. 2019 May;18(3):368-374. doi: 10.1016/j.jcf.2018.12.011. Epub 2018 Dec 28. J Cyst Fibros. 2019. PMID: 30595473 Free article.
[Inhaled treatments in cystic fibrosis: what's new in 2013?].
Dubus JC, Bassinet L, Chedevergne F, Delaisi B, Desmazes-Dufeu N, Reychler G, Vecellio L; GRAM (Groupe aérosols et mucoviscidose de la Société française de mucoviscidose). Dubus JC, et al. Among authors: chedevergne f. Rev Mal Respir. 2014 Apr;31(4):336-46. doi: 10.1016/j.rmr.2013.12.001. Epub 2014 Jan 4. Rev Mal Respir. 2014. PMID: 24750953 Review. French.
The role of inflammation in childhood asthma.
Chedevergne F, Le Bourgeois M, de Blic J, Scheinmann P. Chedevergne F, et al. Arch Dis Child. 2000 Jun;82 Suppl 2(Suppl 2):II6-9. doi: 10.1136/adc.82.suppl_2.ii6. Arch Dis Child. 2000. PMID: 10833470 Free PMC article. Review.
Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR.
Drummond D, Dana J, Berteloot L, Schneider-Futschik EK, Chedevergne F, Bailly-Botuha C, Nguyen-Khoa T, Cornet M, Le Bourgeois M, Debray D, Girard M, Sermet-Gaudelus I. Drummond D, et al. Among authors: chedevergne f. J Cyst Fibros. 2022 Mar;21(2):212-219. doi: 10.1016/j.jcf.2021.07.018. Epub 2021 Aug 26. J Cyst Fibros. 2022. PMID: 34454846 Free article.
Profiling the response to lumacaftor-ivacaftor in children with cystic between fibrosis and new insight from a French-Italian real-life cohort.
Cornet M, Robin G, Ciciriello F, Bihouee T, Marguet C, Roy V, Lebourgeois M, Chedevergne F, Bonnel AS, Kelly M, Reix P, Lucidi V, Stoven V, Sermet-Gaudelus I. Cornet M, et al. Among authors: chedevergne f. Pediatr Pulmonol. 2022 Dec;57(12):2992-2999. doi: 10.1002/ppul.26123. Epub 2022 Sep 6. Pediatr Pulmonol. 2022. PMID: 35996214 Free PMC article.
Might Brushed Nasal Cells Be a Surrogate for CFTR Modulator Clinical Response?
Pranke I, Hatton A, Masson A, Flament T, Le Bourgeois M, Chedevergne F, Bailly C, Urbach V, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Pranke I, et al. Among authors: chedevergne f. Am J Respir Crit Care Med. 2019 Jan 1;199(1):123-126. doi: 10.1164/rccm.201808-1436LE. Am J Respir Crit Care Med. 2019. PMID: 30326728 No abstract available.
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C; French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC. Am J Respir Crit Care Med. 2021. PMID: 33600738
Vaccine coverage in CF children: A French multicenter study.
Masson A, Launay O, Delaisi B, Bassinet L, Remus N, Lebourgeois M, Chedevergne F, Bailly C, Foucaud P, Corvol H, deBlic J, Sermet-Gaudelus I. Masson A, et al. Among authors: chedevergne f. J Cyst Fibros. 2015 Sep;14(5):615-20. doi: 10.1016/j.jcf.2015.04.006. Epub 2015 May 16. J Cyst Fibros. 2015. PMID: 25985911 Free article. Clinical Trial.
22 results